At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 752 enrolled
Drug / intervention
Aspirin, acetaminophen and caffeine +2 moredrug
Likely dose
Aspirin, acetaminophen and caffeine 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Parallel-group Single-dose, Placebo-controlled Study Comparing the Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine.
In Brief
A Phase 4 clinical trial evaluating Aspirin, acetaminophen and caffeine, Sumatriptan, and 1 other intervention for Pain, Migraine. Completed, enrolled 752 participants across 20 sites.
Detailed Summary
The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Migraine
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedNov 2010
Primary CompletionMar 2011
TodayJul 2026
First PostedNov 25, 2010
Enrollment StartNov 1, 2010
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.6 years ago
Interventions
Aspirin, acetaminophen and caffeinedrug
2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
Sumatriptandrug
100 mg Sumatriptan
Placebodrug
placebo